Together We Can Stop Diabetes. Expanding Research to Advance Treatment and a Cure

Size: px

Start display at page:

Download "Together We Can Stop Diabetes. Expanding Research to Advance Treatment and a Cure"

Todd Cummings
5 years ago
Views:

1 Together We Can Stop Diabetes Expanding Research to Advance Treatment and a Cure

2 Robert E. Ratner, MD FACP, FACE, Chief Scientific & Medical Officer Tamara Darsow, PhD Vice-President of Research

3 Tamara Darsow, PhD Vice-President of Research

4 Betsy Seaquist, MD Vice President, Medicine and Science John Anderson, MD President-Elect, Medicine and Science Vivian Fonseca, MD President, Medicine and Science Sam Dagogo-Jack, MD Chair, Research Grant Review and BOD member Al Powers, MD Chair, Research Policy Committee Vincent Poitout, PhD, DVM Research Policy Committee and BOD member

5 Strategic Objective for Research Expand the field of diabetes research to accelerate progress toward a cure and improved treatments By the end of 2015: Increased number of career development award recipients who receive subsequent federal funding in the field of diabetes research Increased federal funding for diabetes research Increased Association funding for diabetes research

6 The American Diabetes Association has been supporting diabetes research in the academic community for more than half a century, significantly contributing to the diabetes research landscape. Since inception of the Program in 1952 Nearly 4,000 research projects have been funded More than $600 million has been invested in diabetes research

7 In 2011 the Program supported: Nearly $34.6 million in diabetes research More than 400 active research projects 139 leading academic research institutions

8 Research Program Successes 6 17% 56% 98% 47% Publications per award Receive patents Receive promotions Remain in diabetes research Receive recognition awards

9 85% of investigators received subsequent federal funding to support their work Investigators leveraged Association support into a 7.5 fold increase in funding from other sources Association funding provides the seed for expanding the field of diabetes research

11 Research Program Successes Panel Sam Dagogo-Jack, MD Chair, Research Grant Review and BOD member Al Powers, MD Chair, Research Policy Committee Vincent Poitout, PhD, DVM Research Policy Committee and BOD member

12 Kenneth Cusi, MD University of Florida College of Medicine Clinical Translational Award Role of Early Screening and Intervention for Fatty Liver Disease (NAFLD) in a Predominantly Hispanic Population with Type 2 Diabetes Mellitus (T2DM)

13 Chih-Pin Liu, Ph.D. City of Hope, Beckman Research Institute Basic Science Award Tolerance Induction and Inhibition of Type 1 Diabetes

14 Alyssa H. Hasty, Ph.D. Vanderbilt University Medical Center ADA-Ethicon Endosurgery/Covidien Research Award in Bariatric Surgery and Diabetes Impact of Bariatric Surgery on Resolution of Inflammation in Adipose Tissue

15 I m Here to Stop Diabetes

16 Robert E. Ratner, MD FACP, FACE, Chief Scientific & Medical Officer

17 Communication and Translation Accelerating Research Advances to Patients

18 Research is Central to the Mission Professional Resources Scientific Sessions Professional education Peer-reviewed journals DiabetesPro Advocacy Research support Diabetes prevention and care Legal advocacy and support Legislative action RESEARCH Direct research funding Medical Information Clinical Practice Recommendations (treatment guidelines) Medical publications Communities Community health education programs Center for Information & Community Support Forecast magazine Diabetes.org

19 US Diabetes Therapeutic Advances 1st ADA Standards of Care 1989 Bromocript DPP-4 Pramlintide Insulin SFU GLP-1R agonist TZD Rapid-acting insulin αglucosidase inhibitor Metformin Meglitinide Basal insulin

20 Transformation of Diabetes Management Type 2 Diabetes Beef/Pork Insulin and SFUs Average HbA 1c ~ 9% Complications -common, etiology not clear ADA treatment algorithm Multiple oral/injection options Average HbA 1c ~ 7.5% Complications -less frequent, etiology(ies) well-defined

21 Transformation of Diabetes Management Type 1 Diabetes Animal Insulins Average HbA 1c >9% Life Expectancy-reduced Hypoglycemic Episodes Minimal Monitoring Methods Complications Childbearing? Human and analog insulins, pens or pumps, basal and mealtime CGMS, Self Glucose Monitoring Average HbA 1c < 8% Life Expectancy-near normal

Professional Journals Diabetes Basic Research with circulation of 5,000 Rank 1 st among diabetes journals, Impact factor of 8.3 2.

22 Professional Journals Diabetes Basic Research with circulation of 5,000 Rank 1 st among diabetes journals, Impact factor of million online visits with 5.5 million total page views Diabetes Care Clinical Research with circulation of 12,000 Rank 2nd among diabetes journals, Impact factor

Professional Journals Clinical Diabetes Target audience of primary care physicians Circulation: 29,000 713,000 online visits with 1.

23 Professional Journals Clinical Diabetes Target audience of primary care physicians Circulation: 29, ,000 online visits with 1.3 million page views Diabetes Spectrum Target audience of diabetes educators, NPs, and other HCP Circulation: 5, ,000 online visits with 920K total page views

24 Translation of Research Findings Betsy Seaquist, MD Vice President, Medicine and Science John Anderson, MD President-Elect, Medicine and Science Vivian Fonseca, MD President, Medicine and Science

25 I m Here to Stop Diabetes

Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes

Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement